Genentech, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$21Mgeneral payments (2019-2025)
$5.5Mresearch payments (2019-2025)
11,674clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Vabysmo $424K associated (2023-2025)
- Ocrevus $316K associated (2023-2025)
- Xolair $225K associated (2023-2025)
- Columvi $199K associated (2023-2025)
- Venclexta $198K associated (2023-2025)
- Susvimo $176K associated (2023-2025)
- Tnkase $114K associated (2023-2025)
- Tecentriq $108K associated (2023-2025)
- Polivy $102K associated (2023-2025)
- Evrysdi $101K associated (2023-2025)
- Enspryng $100K associated (2023-2025)
- Lucentis $59K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Michael Grundman | San Diego, CA | $1,487,500.00 | |
| Mandar Muzumdar | New Haven, CT | Medical Oncology | $370,500.00 |
| Miriam Bloch | La Jolla, CA | Anatomic Pathology & Clinical Pathology | $251,650.00 |
| Malte Schutz | Chicago, IL | $235,673.71 | |
| Boyu Hu | Houston, TX | Hematology & Oncology | $225,000.00 |
| Reid Merryman | Boston, MA | Medical Oncology | $225,000.00 |
| Ariel Lefland | New Haven, CT | Neurology (Psychiatry & Neurology) | $219,277.00 |
| Kevin Leslie | Phoenix, AZ | Anatomic Pathology & Clinical Pathology | $206,183.13 |
| Paunel Agyei | Weston, FL | Neurology (Psychiatry & Neurology) | $201,000.00 |
| Sahaja Acharya | Baltimore, MD | Radiation Oncology | $200,000.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.